Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations
Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, today announced four leadership appointments across the organization.
Who to call at Avalyn, and when
A new leader at Avalyn brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Avalyn raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Avalyn, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Avalyn
Location
245 First Street, 18th Floor
Cambridge, Massachusetts, United States
About
Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Our lead candidate, AP01, is an optimized inhaled formulation of pirfenidone, currently being studied for progressive pulmonary fibrosis in the Phase 2b MIST study. In addition, we completed two Phase 1 studies for AP02, an optimized inhaled formulation of nintedanib. At Avalyn, we are driven by our mission to empower lives through breakthrough inhaled therapies for interstitial lung diseases, turning breathlessness into hope.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Avalyn changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.